Trouble at Wockhardt Limited
|
|
ICMR HOME | Case Studies Collection
To download Trouble at Wockhardt Limited case study (Case Code: FINC084) click on the button below, and select the case from the list of available cases:
OR
»
Finance Case
Studies
» Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Area Specific Case Studies
» Industry Wise Case Studies
» Company Wise Case Studies
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
Case Details: |
Price: |
| Case Code |
: |
FINC084 |
For delivery
in electronic format: Rs. 400;
For delivery through courier (within India): Rs. 400 + Rs. 25 for Shipping & Handling Charges
|
| Case Length |
: |
15 Pages |
| Period |
: |
1959-2008 |
| Pub. Date |
: |
2013 |
| Teaching Note |
: |
Not Available |
| Organization |
: |
Wockhardt Limited |
| Industry |
: |
Pharmaceutical |
| Countries |
: |
India |
Abstract:
|
Wockhardt Limited, which was once a well known pharma major, ended up in financial mess after a spree of acquisitions in India and abroad, in large part through leverage. The increased debt burden and losses in complex currency derivatives hedging left the company in precarious situation. Overcoming these challenges in a gloomy economic environment and in a heavily leveraged condition was a challenge to the company.
|
|
Issues:
Indentify the reasons behind the high growth of Wockhardt.
Analyze the reasons for Wockhardt’s financial troubles.
Analyze the various options available for Wockhardt to overcome the challenges.
Contents:
Keywords:
Financial performance, Wockhardt Founder, Wockhardt, Habil Khorakiwala, europe, Wockhardt Ltd., Wockhardt, Growth, FCCB, stock prices, Pharma company, Worli Chemical Works, RR Medi Pharma Ltd., Wallis Laboratories, Merind Ltd., CP Pharmaceuticals, Esparma GmbH, Dumex India Pvt. Ltd., Pinewood Laboratories, Negma Laboratories, Morton Grove Pharmaceuticals, RR Medi Pharma Ltd., Wallis Laboratories, Leverage, Financial Distress, Debt-Equity ratio
Introduction
- Next Page>>
|
|
